In this review
Choose the exact Platinum
OMRON Platinum BP5465 is a sensible choice for two people who want a readable home blood-pressure record without making the phone the center of every measurement. OMRON lists a US MSRP of $90.99. Its two-user memory and dual display are the practical selling points; the AFib screening feature requires more careful interpretation. [1]
Check the model number on the listing and carton. Platinum has appeared on other OMRON monitors, including BP5450. A familiar product name does not mean the display, rhythm features or instructions are identical. This review covers BP5465, so a discount on a different generation deserves a separate comparison.
A household record is its strongest feature
The manufacturer specifies 200 stored readings, divided into 100 for each of two users, with a guest mode. Its backlit screen can show the current result alongside the previous reading, except when AFib is detected. TruRead can take three consecutive readings and display their average, with adjustable intervals. [1]
That arrangement works best when each person reliably selects the right profile. It makes less sense if several relatives will share one pair of user slots. Mixed records can undermine an otherwise convenient device. Decide whether the on-device history or the connected report will be the record you bring to an appointment; either needs the correct person attached to it.
For the evidence behind this decision, read Home blood pressure: a useful record needs a treatment pathway.
Cuff fit comes before connectivity
The included wide-range D-ring cuff fits upper arms measuring 9–17 inches in circumference. The product includes an AC adapter and storage case. OMRON also describes Bluetooth transfer through its connect app for compatible phones. [1] OMRON states that this specific model is not intended for people under 22, pregnant users or people with implanted pacemakers or defibrillators. [1]
Measure your arm before buying, particularly if you are replacing a cuff that felt tight or loose. A large screen cannot compensate for an unsuitable fit. Check the exact phone compatibility if app transfer is the reason for paying more. If a written log already works well, evaluate the purchase on its display, memory and measurement routine instead of counting connected features as an automatic benefit.
Treat an AFib flag as a reason to follow up
OMRON describes the monitor as screening for the possibility of AFib during a blood-pressure measurement. That wording matters. A screening signal is not the same thing as an interpretable ECG trace or a confirmed diagnosis. The product page also describes a weekly average of detected AFib events. [1]
Set a follow-up plan with the clinician who manages your blood pressure before a new alert becomes a source of confusion. Do not make medication changes from the device label alone. Withings BPM Connect is an alternative if automatic connected records are your main priority. KardiaMobile answers a different question by recording a short single-lead ECG. Choose Platinum when its two-person workflow and readable display solve your actual monitoring problem, then judge it by whether the record supports useful care rather than whether it adds another reassuring score.
The dual display is most valuable when it reduces a real reading or recording problem. Someone who struggles with a small phone screen may reasonably prioritize the monitor’s own interface. Someone who already maintains a clear log may gain less. Compare those everyday requirements before paying for rhythm-screening extras, because the additional alert can create another question to resolve rather than making the blood-pressure record inherently easier to use.
A connected consideration is Personal ECGs: detecting more AF is not the same as preventing stroke. It answers a different part of the decision.
Understanding the cost
Manufacturer US MSRP $90.99; actual authorized-retailer price, tax and accessory costs can differ. No recurring payment is represented as mandatory or included.
Build your cost estimateSources
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.